New diabetes drug HM11260C aims to lower blood sugar in phase 3 trial
NCT ID NCT07379333
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests an experimental drug called HM11260C in adults with type 2 diabetes whose blood sugar is not well controlled with metformin and dapagliflozin. About 118 participants will receive either HM11260C or a placebo, and researchers will measure changes in HbA1c (a key blood sugar marker) over 36 weeks. The goal is to see if this new drug can safely improve blood sugar levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HM11260C (an experimental drug for diabetes)
What this could lead to
If successful, this could provide a new treatment option for people with type 2 diabetes who need better blood sugar control.
What could go wrong
This is still an experimental drug in a relatively small Phase 3 trial. It may not prove more effective than existing treatments, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Catholic University of Korea Bucheon St. Mary's Hospital
RECRUITINGGyeonggi-do, South Korea
Contact Email: •••••@•••••
Contact